Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Marshall-Smith syndrome is a rare genetic disease characterized by tall stature and advanced bone age at birth.
Features include always present findings: Decreased body weight, Proptosis, High forehead, and Moderate intellectual disability and others; and very common findings: Hypertrichosis, Midface retrusion, Delayed speech and language development, and Blue sclerae and others. 100 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 9 | Thoracic kyphosis, Thoracic scoliosis, Recurrent fractures |
Brain and nerves | 7 | Hydrocephalus, Enlarged brain ventricles (ventriculomegaly), Delayed speech and language development |
Lungs and breathing | 7 | Recurrent upper respiratory tract infections, High blood pressure in lung arteries (pulmonary arterial hypertension), Recurrent aspiration pneumonia |
Arms and legs | 4 | Prominent fingertip pads, Clinodactyly of the 5th finger, Bullet-shaped middle phalanges of the hand |
Heart and blood vessels | 4 | High blood pressure in lung arteries (pulmonary arterial hypertension), Premature ventricular contraction, Dysplastic aortic valve |
Growth and development | 3 | Short stature, Tall stature, Failure to thrive |
Head and neck | 3 | High palate, Triangular face, Craniosynostosis |
Muscles | 3 | Low muscle tone (hypotonia), Axial hypotonia, Brain shrinkage (cerebral atrophy) |
Ears | 2 | Hearing loss (hearing impairment), Bilateral conductive hearing impairment |
Digestive system | 2 | Cholesteatoma, Feeding difficulties |
Eyes | 2 | Glaucoma, Optic nerve hypoplasia |
Blood and immune system | 1 | Recurrent upper respiratory tract infections |
NFIX-related Malan syndrome (MALNS) was first reported in three individuals with overgrowth and heterozygous pathogenic variants in NFIX in 2010 . Since that time, at least 100 individuals have been identified with MALNS [, , , , , , , , , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. NFIX-Related Malan Syndrome: Frequency of Select Features
System | Feature | % of Persons w/Feature1 | Comment |
|---|---|---|---|
Facial | Distinctive facial features | 100% | — |
Growth |
NFIX encodes nuclear factor I X (502 aa). Recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. Highest expression in Brain Cerebellar Hemisphere (225.6 TPM) and Brain Cerebellum (208.3 TPM).
Marshall-Smith syndrome is caused by mutations in the NFIX gene on chromosome 19.
NFIX is classified as a druggable target (Transcription Factor category) with score 0.0.
No consensus clinical diagnostic criteria for NFIX-related Malan syndrome (MALNS) have been published.
MALNS should be suspected in individuals with at least five out of the following eight features [, , , ]:
Prenatal overgrowth, often with a diagnosis of being large for gestational age
Postnatal overgrowth (length/height and/or head circumference ≥2 standard deviations [SD] above mean for age and sex)
Developmental delay/ intellectual disability
Behavioral problems
Distinctive facial features (See .)
Advanced bone age and/or skeletal anomalies, such as scoliosis, pes planus, and pectus anomaly
Slender body habitus
Ocular findings, most commonly strabismus, refractive errors, and blue sclerae
Source: GeneReviews — "NFIX-Related Malan Syndrome"
(SS), a syndromic overgrowth condition, is the primary differential diagnosis of NFIX-related Malan syndrome (MALNS). SS and MALNS are phenotypically similar and have overlapping clinical presentations but are distinguished by significant differences in the severity and frequency of several key features.
Source: GeneReviews — "NFIX-Related Malan Syndrome"
Genetic testing for NFIX is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for Marshall-Smith syndrome. The disease remains an area of unmet medical need.
Suggested management and follow up recommendations for individuals with NFIX-related Malan syndrome (MALNS) have been published .
To establish the extent of disease and needs in an individual diagnosed with MALNS, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
NFIX-Related Malan Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measurement of weight, length/height, head circumference | To assess for macrocephaly postnatal overgrowth
Calculate BMI calorie intake. | In those age 2 years
Gastrointestinal/
| Assess dietary intake variety of foods eaten. | • Consider eval for gastrostomy tube placement in persons w/dysphagia /or aspiration risk.
If BMI is 2 SD below mean for age sex, reevaluate appropriateness of reported caloric intake.
Assess for signs/symptoms of constipation. |
Physical exam | • To screen for hepatomegaly, although most hepatomegaly described to date has not been assoc w/liver dysfunction
Consider abdominal ultrasound if hepatomegaly is suspected by physical exam.
| Neurologic eval, incl for signs/symptoms of Chiari I malformation1 | Brain MRI should be considered for those w/concerning symptoms of Chiari I malformation or in those w/seizures.
Assess for signs/symptoms of seizures. | • Consider EEG if seizures are a concern.
Source: GeneReviews — "NFIX-Related Malan Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "NFIX-Related Malan Syndrome"
View trials for Marshall-Smith syndrome
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. NFIX-Related Malan Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Growth/Nutrition | Measurement of growth parameters | At each visit; 1st BMI eval should be performed after age 2 yrs. Assessment of caloric intake BMI (in those age 2 yrs)1 |
Psychiatric | Monitor developmental progress, educational needs, psychopathologic symptoms. | From age 12 mos to approximatively 36 mos: annually; From age 3 yrs to adulthood: every 2 yrs |
Musculoskeletal | Physical medicine, OT/PT assessment of mobility, presence or progression of scoliosis/kyphosis, pes planus, pectus anomaly | At each visit Consider DXA eval for bone mineral density. |
Eyes/Vision | Ophthalmology eval | Annually until puberty; Periodic eval should be performed in adults to evaluate for late-onset optic nerve degeneration. |
Hearing | Audiology eval | Annually in childhood or as clinically indicated |
ENT/Mouth | Routine dental/orthodontic evals | At least annually |
Cardiovascular | Cardiology eval, w/consideration of echocardiogram | If baseline eval is normal, consider annual cardiology follow up. |
Source: GeneReviews — "NFIX-Related Malan Syndrome"
Phenotype severity distribution: 7 always present features, 6 very common features, 54 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Marshall-Smith syndrome.
8 publications have been identified in PubMed for Marshall-Smith syndrome. Research spans Basic Science / Preclinical (38%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Ay A (2025). [PMID: 40125923](https://pubmed.ncbi.nlm.nih.gov/40125923/). *Ophthalmic genetics*. [Case Report / Case Series]
Ardhanari M (2025). [PMID: 41550105](https://pubmed.ncbi.nlm.nih.gov/41550105/). *CASE (Philadelphia, Pa.)*. [Review / Meta-Analysis]
Gąsiorowska J (2025). [PMID: 41693191](https://pubmed.ncbi.nlm.nih.gov/41693191/). *Pediatric endocrinology, diabetes, and metabolism*. [Basic Science / Preclinical]
Zhou W (2024). [PMID: 39126371](https://pubmed.ncbi.nlm.nih.gov/39126371/). *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. [Gene Therapy / Novel Therapeutics]
Lin XQ (2024). [PMID: 39014953](https://pubmed.ncbi.nlm.nih.gov/39014953/). *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. [Case Report / Case Series]
Zhao J (2024). [PMID: 38168088](https://pubmed.ncbi.nlm.nih.gov/38168088/). *American journal of medical genetics. Part A*. [Basic Science / Preclinical]
Kooblall KG (2024). [PMID: 38827116](https://pubmed.ncbi.nlm.nih.gov/38827116/). *JBMR plus*. [Basic Science / Preclinical]
Khurana E (2024). [PMID: 38647663](https://pubmed.ncbi.nlm.nih.gov/38647663/). *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 6:34 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Marshall-Smith syndrome
Macrocephaly
100% |
77% of adults maintain a head circumference 2 SD above mean. |
Postnatal length/height 2 SD above mean | 56% | Final adult height falls w/in 2 SD of mean in two thirds of affected persons. | — |
Neurologic | Developmental delay/ intellectual disability | 100% | May vary from moderate to severe |
Hypotonia | 65% | — | — |
Epilepsy/ EEG anomalies | 10/16 (63%)2 | Persons w/contiguous deletion incl NFIX surrounding genes have higher risk of epilepsy compared to those w/intragenic NFIX pathogenic variant. | — |
Autonomic signs | 4/16 (25%)2 | Incl episodic ataxia w/dizziness nausea /or postural fainting | — |
Neurobehavioral/psychiatric manifestations | 12/14 (86%)2,3 | 10/15 (67%)2 showed hypersensitivity to noise.3 | — |
Musculoskeletal | Slender body habitus | 16/16 (100%)2 | — |
Advanced bone age | 76% | — | — |
Abnormal spine curvature | 12/16 (75%)2 | — | — |
Pectus carinatum, excavatum, or mixed | 10/16 (63%)2 | — | — |
Pes planus | 11/16 (69%)2 | — | — |
Long hands fingers | 10/16 (63%)2 | — | — |
Long bone fractures | 5/16 (31%)2 | — | — |
Eye | Refractive errors | 75% | — |
Strabismus | 10/16 (63%)2 | — | — |
Esotropia | 9/16 (56%)2 | — | — |
Nystagmus | 5/16 (31%)2 | — | — |
Blue sclerae | 11/16 (69%)2 | Mainly persisting after infancy | — |
Cataract | 2/16 (13%)2 | Mainly polar posterior cataract | — |
Optic nerve hypoplasia | 25% | — | — |
Cardiovascular | Cardiovascular anomalies | 4% | Low-grade mitral regurgitation is most common finding;4 other CHD aortic root dilatation are less common but require assessment monitoring . |
Mouth | Malocclusion | 7/16 (44%)2 | — |
Ogival (narrow) palate/ dental crowding | 9/16 (56%)2 | — | — |
Dental caries | 6/16 (38%)2 | — | — |
Oral apraxia/ hypersalivation | 31% (5/16)2 | — | — |
Other | Constipation | 50% (8/16)2 | — |
Hepatomegaly | 25% (4/16)2 | — | — |
Low BMI | 38% (6/16)2 | — | — |
Cryptorchidism | 13% (2/16)2 | — | — |
Hearing loss | 2% | Of the 2 reported persons w/this finding, both had sensorineural hearing loss. Adapted from and BMI = body mass index; CHD = congenital heart defects; SD = standard deviations Percentages refer to individuals with a pathogenic variant in NFIX. | — |
Source: GeneReviews — "NFIX-Related Malan Syndrome"